United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.www.unither.com
1
MENTIONS
1
EPISODES
1
PODCASTS
Search complete. 1 mention across 1 episode found for "United Therapeutics Corporation".
Oct 21, 2026
Amanda ForysGUEST
Our firm's been in place for about four and a half years, and we work with our clients on really understanding that intersection of everything going on in our policy environment and how that affects coverage, the need for evidence generation, and just general market access trends.
Amanda ForysGUEST
Previously, I was the senior director of policy pricing and reimbursement at United Therapeutics, and also have worked in consulting for more years than I'd like to admit.
Amanda ForysGUEST
My background's mostly been in assessing federal policy, Medicare coverage.
Amanda ForysGUEST
We do Congressional budget office scoring and general economic impact analyses.